KannaLife

Kannalife Sciences Inc.

Company type	Private (Subsidiary)
Industry	Pharmaceutical
Founded	2010
Founders	Dean Petkanas, Thoma Kikis
Headquarters	Doylestown, Pennsylvania
Total assets	Exclusive License of patent US 6630507
Website	http://kannalife.com

KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507   “Cannabinoids as Antioxidants and Neuroprotectants."

Kannalife Sciences Inc. , a subsidiary of Neuropathix, Inc., is a bio-pharmaceutical and phyto-medical company based in Doylestown, Pennsylvania founded by Dean Petkanas and Thoma Kikis. ^[1] Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. ^[2]

History

In 2011, the company was granted an Exclusive License ^[3] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507  , “Cannabinoids as Antioxidants and Neuroprotectants." ^[4]

In 2021, Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH). ^[5] The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain. ^[6] In 2024, The Michael J. Fox Foundation awarded Kannalife a $1.49 Million grant to support the development of KLS-13019 as a potential treatment for Parkinson's disease. ^[7] This funding aims to advance preclinical research into KLS-13019, a therapeutic targeting neuroinflammation and mitochondrial dysfunction associated with Parkinson's disease. ^[7]

Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County ^[8] to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Parkinson's disease, Mild Traumatic Brain Injury and CTE.^{[ citation needed ]}

Kannalife was featured in Sports Illustrated article on using cannabinoids to treat Concussions and CTE. ^[9]

External links

Patent US 6630507

https://www.kannalife.com/

References

1. Guion, Payton (November 12, 2014). "The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage". VICE News. Archived from the original on May 8, 2015. Retrieved 2014-12-12.
2. Leland, John (October 31, 2014). "For Pot Inc., the Rush to Cash In Is Underway". The New York Times. Retrieved 2014-10-31.
3. "Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans". federalregister.gov. Retrieved 2011-11-17.
4. "Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT)". thestreet.com. Retrieved 2012-07-09.
5. "Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)". Biospace. 28 September 2021. Retrieved 2021-09-28.
6. "Development of KLS-13019 for Neuropathic Pain". reporter.nih.gov. Retrieved 2021-09-28.
7. Lobo, Andrea (July 1, 2024). "MJFF $1.49M grant to advance preclinical research into KLS-13019". Parkinson's News Today. Retrieved 2024-07-01.
8. www.bizjournals.com https://www.bizjournals.com/philadelphia/news/2024/06/28/kannalife-doylestown-parkinsons-fox-foundation.html . Retrieved 2025-08-14.{{cite web}}: Missing or empty |title= (help)
9. "How cannabis is helping one company research treatment of CTE". Sports Illustrated. July 12, 2016.